Schizophrenia drugs market seen topping $11.3B by 2030

The global schizophrenia drugs market is forecast to exceed $11.3 billion by 2030, driven by newer antipsychotics, expanding treatment access and stronger adoption of clinical guidelines. North America is expected to remain the largest regional market, while second-generation drugs stay the category leader.

Why it matters: - Schizophrenia treatment is becoming a larger commercial and clinical priority as new therapies widen options for patients and prescribers. - The market’s growth reflects rising diagnosis, broader care access and more use of long-acting and next-generation medicines. - The segment is also becoming more competitive as established drugmakers defend share with new formulations and digital support tools.

What happened: - The Business Research Company projected that the global schizophrenia drugs market will surpass $11.3 billion by 2030. - The market is forecast to grow at a 6% compound annual growth rate through 2030. - The report estimates the schizophrenia drugs market will account for about 34% of the broader antipsychotic drugs market by 2030. - The report also places schizophrenia drugs at close to 0.5% of the overall pharmaceuticals industry in 2030.

The details: - Second-generation, third-generation and other therapeutic classes are projected to add more than $3.2 billion to the market by 2030. - Second-generation drugs are expected to contribute $2 billion of that increase. - Third-generation drugs are projected to add $1 billion. - Other therapeutic classes are forecast to add $0.2 billion. - Second-generation antipsychotics are projected to remain the largest class in 2030, with a 71% share and about $8 billion in value. - The report says second-generation drugs are favored because they work against both positive and negative symptoms, have better tolerability than first-generation drugs, and benefit from growing generic availability. - Oral and injectable medicines remain the two main treatment types in the market. - Distribution runs through hospital pharmacies, retail pharmacies, online pharmacies and other outlets. - North America is expected to stay the largest regional market in 2030 at $4.1 billion, up from $3.2 billion in 2025. - The United States is projected to be the largest national market at $3.6 billion in 2030, rising from $2.8 billion in 2025. - The report lists Otsuka Pharmaceutical Co Ltd. and Johnson & Johnson Services Inc. as the top companies in 2025, each with 9% market share. - H. Lundbeck A/S is listed at 5%. - Bristol Myers Squibb is listed at 2%. - Teva Pharmaceutical Industries Ltd. is listed at 2%. - AbbVie Inc., Eli Lilly and Company, Vanda Pharmaceuticals, Sumitomo Pharma Co Ltd and Pfizer Inc. are each listed at 1%. - The top ten companies accounted for 33% of total market revenue in 2025. - The report identifies high regulatory and technological barriers to entry, including drug approval demands and safety requirements for psychiatric medicines. - A free sample is available here. - The full report is available here.

Between the lines: - The market’s momentum is being shaped by a mix of medical need and commercial execution, not by one single breakthrough. - Emerging therapies like Bristol Myers Squibb’s Cobenfy point to a broader shift toward novel mechanisms and better tolerability. - Bristol Myers Squibb gained FDA approval for Cobenfy in September 2024. - Cobenfy combines xanomeline and trospium chloride and targets cholinergic receptors. - The report says the drug offers symptom relief with fewer side effects than traditional antipsychotics. - Digital health tools are becoming more important as drugmakers try to improve monitoring and medication adherence. - Institutional adoption of guideline-based care is also supporting more standardized treatment decisions.

What's next: - The report expects continued growth from increasing schizophrenia prevalence and aging populations. - It also expects more demand as healthcare infrastructure expands in emerging markets. - Hospitals and psychiatric facilities are likely to keep adopting evidence-based protocols and newer antipsychotic treatments. - North America is expected to retain its leadership position through 2030, supported by reimbursement, clinical research and broader access to specialty care.

The bottom line: - Schizophrenia drugs are moving from a niche psychiatric category into a steadier growth market, powered by innovation, broader access and a heavier reliance on newer antipsychotic therapies.